|
gptkbp:instanceOf
|
gptkb:drug
small molecule
|
|
gptkbp:administeredBy
|
gptkb:vemurafenib
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EE39
|
|
gptkbp:brand
|
gptkb:Cotellic
|
|
gptkbp:CASNumber
|
934660-93-2
|
|
gptkbp:chemicalFormula
|
C21H21F3IN3O2
|
|
gptkbp:developer
|
gptkb:Genentech
gptkb:Roche
|
|
gptkbp:eliminationHalfLife
|
44 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cobimetinib
|
|
gptkbp:indication
|
BRAF V600E or V600K mutation-positive melanoma
|
|
gptkbp:KEGGID
|
D10560
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
MEK inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
473.3 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
25102825
CHEMBL2219416
DB11651
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
rash
photosensitivity
liver toxicity
|
|
gptkbp:synonym
|
gptkb:GDC-0973
|
|
gptkbp:target
|
gptkb:MAP2K1
gptkb:MEK1
|
|
gptkbp:UNII
|
2LZ6X9L7ZO
|
|
gptkbp:usedFor
|
gptkb:cancer
melanoma
|
|
gptkbp:bfsParent
|
gptkb:MAP2K1
gptkb:MAP2K1_gene
gptkb:MEK1/2
gptkb:MAPKK1
gptkb:Mitogen-activated_protein_kinase_kinase_1
|
|
gptkbp:bfsLayer
|
7
|